Interojo Co

Interojo Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Interojo Co (119610.KQ) as of Oct 21, 2026 is 4.81. In the previous year, Total Debt to EBITDA Ratio was 9.20 — a change of -47.73% (lower).

Debt/EBITDA

4.81

YoY

-47.73%

Last updated:

Total Debt to EBITDA Ratio of Interojo Co is 2024 4.81 . Total Debt to EBITDA Ratio of Interojo Co was 2023 9.20 . It decreases by -47.73% lower compared to the previous year.

The Interojo Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.08 KRW
Jan 1, 2018
0.35 KRW
Jan 1, 2019
0.86 KRW
Jan 1, 2020
2.02 KRW
Jan 1, 2021
0.83 KRW
Jan 1, 2022
1.41 KRW
Jan 1, 2023
9.20 KRW
Jan 1, 2024
4.81 KRW
The Interojo Co Debt/EBITDA history
YEARDebt/EBITDAYoY
4.81-47.73%
9.20+552.09%
1.41+70.97%
0.83-59.22%
2.02+135.82%
0.86+148.75%
0.35+335.25%
0.08-52.04%
0.17-61.79%
0.43-53.13%
0.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

Total Debt to EBITDA Ratio of Interojo Co is 4.81 in 2024.

Total Debt to EBITDA Ratio of Interojo Co changed from 9.20 to 4.81, representing a -47.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Interojo Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Interojo Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Interojo Co

All Key Metrics — Interojo Co